Skip to main content
Fig. 11 | Head & Face Medicine

Fig. 11

From: Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro study

Fig. 11

Detection of cell viability (%) with an MTT assay for the different treatment types and times for each of the individual cell types and the cisplatin reference value, (Fig. 11a: Cal 27, Fig. 11b: FaDu, Fig. 11c: OSC 19). Line graph is used to present the results (mean and error bars 95% CI is shown for all three cell lines, (for each treatment time per cell type n = 15)

Back to article page

Head & Face Medicine

ISSN: 1746-160X

Contact us